Drug Trial Radar · NCT05879107
Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
Last checked: Nov 20, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,113
Actual
Start
May 26, 2023
Primary completion
Dec 6, 2023
Study completion May 7, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccineBiological
One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
PCV20Biological
One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted Geometric Mean Titers (GMT) of Opsonophagocytic (OP) Titers at 1 Month After the PCV20 VaccinationTime frame: At Day 31
- Adjusted GMTs of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers [Estimated Dilution 60 (ED60)] at 1 Month After the RSVPreF3 OA VaccinationTime frame: At Day 31 for Co-administration Group and at Day 61 for Control Group
- Adjusted GMTs of RSV-B Neutralizing Titers (ED60) at 1 Month After the RSVPreF3 OA VaccinationTime frame: At Day 31 for Co-administration Group and at Day 61 for Control Group
Locations
38 sites in 4 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Guntersville, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Modesto, California
GSK Investigational Site
Hamden, Connecticut
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
DeLand, Florida
GSK Investigational Site
Jupiter, Florida
GSK Investigational Site
Largo, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
West Des Moines, Iowa
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Troy, Michigan
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
North Charleston, South Carolina
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Frisco, Texas
GSK Investigational Site
Mesquite, Texas
GSK Investigational Site
Plano, Texas
GSK Investigational Site
Antwerp, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Kluisbergen, Belgium
GSK Investigational Site
Mechelen, Belgium
GSK Investigational Site
Namur, Belgium
GSK Investigational Site
Wetteren, Belgium
GSK Investigational Site
Krakow, Poland
GSK Investigational Site
Lodz, Poland
GSK Investigational Site
Lublin, Poland
GSK Investigational Site
Pu?awy, Poland
GSK Investigational Site
Staszów, Poland
GSK Investigational Site
Warsaw, Poland
GSK Investigational Site
Warsaw, Poland
GSK Investigational Site
Warsaw, Poland
GSK Investigational Site
Wroclaw, Poland
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.